1668565-74-9Relevant articles and documents
Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
Williams, David K.,Markwalder, Jay A.,Balog, Aaron J.,Chen, Bin,Chen, Libing,Donnell, Jennifer,Haque, Lauren,Hart, Amy C.,Mandal, Sunil K.,Nation, Andrew,Shan, Weifang,Vite, Gregory D.,Covello, Kelly,Hunt, John T.,Jure-Kunkel, Maria N.,Seitz, Steven P.
, p. 732 - 736 (2018/02/12)
A novel series of o-phenylenediamine-based inhibitors of indoleamine 2,3-dioxygenase (IDO) has been identified. IDO is a heme-containing enzyme, overexpressed in the tumor microenvironment of many cancers, which can contribute to the suppression of the host immune system. Synthetic modifications to a previously described diarylether series resulted in an additional degree of molecular diversity which was exploited to afford compounds that demonstrated significant potency in the HeLa human cervical cancer IDO1 assay..
IDO INHIBITORS
-
Page/Page column 61; 62; 63, (2015/03/16)
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.
